Creative Planning Buys 12,076 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Creative Planning lifted its stake in TG Therapeutics, Inc. (NASDAQ:TGTX) by 34.7% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 46,839 shares of the biopharmaceutical company’s stock after buying an additional 12,076 shares during the period. Creative Planning’s holdings in TG Therapeutics were worth $833,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also made changes to their positions in TGTX. Vanguard Group Inc. lifted its stake in TG Therapeutics by 1.5% during the fourth quarter. Vanguard Group Inc. now owns 13,670,944 shares of the biopharmaceutical company’s stock worth $233,500,000 after purchasing an additional 199,770 shares during the last quarter. Wellington Management Group LLP lifted its stake in TG Therapeutics by 1.4% during the fourth quarter. Wellington Management Group LLP now owns 3,139,764 shares of the biopharmaceutical company’s stock worth $53,627,000 after purchasing an additional 43,290 shares during the last quarter. Opaleye Management Inc. lifted its stake in TG Therapeutics by 2.9% during the first quarter. Opaleye Management Inc. now owns 2,280,000 shares of the biopharmaceutical company’s stock worth $34,679,000 after purchasing an additional 65,000 shares during the last quarter. Marshall Wace LLP bought a new stake in TG Therapeutics during the second quarter worth $36,501,000. Finally, Hood River Capital Management LLC lifted its stake in TG Therapeutics by 6.7% during the second quarter. Hood River Capital Management LLC now owns 1,572,929 shares of the biopharmaceutical company’s stock worth $27,982,000 after purchasing an additional 98,892 shares during the last quarter. 58.58% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

TGTX has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $49.00 target price on shares of TG Therapeutics in a research note on Wednesday, September 18th. B. Riley upped their price target on shares of TG Therapeutics from $29.00 to $34.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group upped their price target on shares of TG Therapeutics from $18.00 to $20.00 and gave the stock a “neutral” rating in a report on Wednesday, August 7th. Two research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, TG Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $31.83.

TG Therapeutics Stock Performance

NASDAQ TGTX opened at $22.18 on Friday. The company has a market capitalization of $3.43 billion, a price-to-earnings ratio of 36.36 and a beta of 2.21. TG Therapeutics, Inc. has a twelve month low of $6.46 and a twelve month high of $26.41. The stock has a fifty day simple moving average of $22.76 and a 200 day simple moving average of $19.02. The company has a quick ratio of 2.83, a current ratio of 3.58 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.04) by $0.08. The business had revenue of $73.47 million during the quarter, compared to the consensus estimate of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. TG Therapeutics’s quarterly revenue was up 357.0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.34) earnings per share. Sell-side analysts expect that TG Therapeutics, Inc. will post 0.13 EPS for the current year.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.